• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Green Mountain Power

Green Mountain Power

  1. ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

    ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

  2. Takeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in Central Nervous System

    Takeda and Affilogic enter into Research Collaboration to Develop Nanofitin®-based Therapies in Central Nervous System

  3. Cambrooke Launches RESTORE Powder and RESTORE Lite Powder, Two Medical Food Hydration Beverages

    Cambrooke Launches RESTORE Powder and RESTORE Lite Powder, Two Medical Food Hydration Beverages

  4. Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results

    Cellectis Reports 2nd Quarter and First Half Year 2016 Financial Results

  5. Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

    Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

  6. Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine

    Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine

  7. ERYTECH Appoints Allene M. Diaz to its Board of Directors

    ERYTECH Appoints Allene M. Diaz to its Board of Directors

  8. ELANIX BIOTECHNOLOGIES AG securing funding, adding staff and moving to larger offices

    ELANIX BIOTECHNOLOGIES AG securing funding, adding staff and moving to larger offices

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.